Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasotraline PK study in pediatric ADHD
NCT02195167Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasotraline in attention deficit hyperactivity disorder (ADHD), sponsored by Sumitomo Pharma America. Primary endpoints: Maximum concentration, Area under the concentration-time curve and 4 more. Started Jul 2014; status: completed.
02
Drugs
dasotraline
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02195167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195167.